Stock NSPR INSPIREMD, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News InspireMD, Inc.

Equities

NSPR

US45779A8466

Delayed Nasdaq
Other stock markets
 03:23:32 2024-04-26 pm EDT 		5-day change 1st Jan Change
2 USD +4.44% Intraday chart for InspireMD, Inc. -4.31% -28.83%
Mar. 06 Transcript : InspireMD, Inc., Q4 2023 Earnings Call, Mar 06, 2024
Mar. 06 Earnings Flash (NSPR) INSPIREMD Posts Q4 Revenue $1.8M MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
AQ
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
AQ
Transcript : InspireMD, Inc., Q4 2023 Earnings Call, Mar 06, 2024
Earnings Flash (NSPR) INSPIREMD Posts Q4 Revenue $1.8M
MT
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
AQ
InspireMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th
AQ
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System
AQ
InspireMD Gets CE Mark Recertification From the European Union
MT
InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework
AQ
InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America
AQ
InspireMD, Inc. Announces Appointment of Pete Ligotti as Executive Vice President and General Manager of North America
CI
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System
AQ
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions
AQ
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions
CI
Transcript : InspireMD, Inc., Q3 2023 Earnings Call, Nov 06, 2023
Earnings Flash (NSPR) INSPIREMD Reports Q3 Revenue $1.6M
MT
InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update
AQ
InspireMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
InspireMD to Participate in Upcoming November Investor Conferences
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NSPR Stock
  4. News InspireMD, Inc.